Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study.
Joseph R HabibBenedict Kinny-KösterAmmar Asrar JavedPiotr ZelgaLily V SaadatRachel C KimMyrte GorrisValentina AllegriniShuichi WatanabeJeremy SharibMassimo ArceritoJörg KaiserKelly J LafaroMin TuManish S BhandareChanjuan ShiMichael P KimCamilo Correa-GallegoLois A DaamenPaul E ObersteinC Max SchmidtNader N HannaPeter AllenMartin LoosShailesh V ShrikhandeI Quintus MolenaarIsabella FrigerioMatthew H G KatzKevin C SoaresYi MiaoMarco Del ChiaroJin HeThilo HackertRoberto SalviaMarkus W BüchlerCarlos Fernandez-Del CastilloMarc G H BesselinkGiovanni MarchegianiChristopher L Wolfgangnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Almost half of patients with resected IPMN-derived PDAC may be overtreated or undertreated. In patients with node-negative disease or normal CA19-9, adjuvant chemotherapy is not associated with a survival benefit, whereas those with node-positive disease and elevated CA19-9 have an associated benefit from adjuvant chemotherapy. A decision tree was proposed. Randomized controlled trials are needed for validation.